Physician profile
Michael T Snitzer
NPI 1619955796
$2,476.58
in general payments reported to CMS, 2019-2025
24 companies · $665 in 2025
The $665 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.85 · 2020: $94.52 · 2021: $42.56 · 2022: $431 · 2023: $428 · 2024: $741 · 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,834.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,833.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $670.92 | 2019-2025 | Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals LP | $405.91 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $282.06 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $133.15 | 2020-2024 | Xarelto |
| Novo Nordisk INC | $128.63 | 2023-2025 | Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $125.75 | 2023-2025 | Camzyos, Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.11 | 2022-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $94.97 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $90.30 | 2023-2024 | Repatha, Evenity, Prolia |
| Novartis Pharmaceuticals Corporation | $79.28 | 2019-2023 | |
| Amarin Pharma, INC. | $44.62 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $37.05 | 2023-2025 | Unithroid |
| Phathom Pharmaceuticals, INC. | $36.28 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $33.78 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.52 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $24.24 | 2019 | |
| Corcept Therapeutics | $23.04 | 2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $22.39 | 2024 | Trintellix |
| Exact Sciences Corporation | $19.55 | 2024 | Cologuard Collection Kit |
| Organogenesis INC. | $18.42 | 2022 | |
| Ibsa Pharma INC. | $17.58 | 2020 | |
| Inspire Medical Systems, INC. | $17.39 | 2025 | Inspire |
| Abbott Laboratories | $15.46 | 2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $12.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Snitzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.